PTCB Medications: generic names, brand names and classes

What this topic actually asks of you

Domain 1 is Medications, and it is the largest domain on the PTCE — 35% of the exam. Two of its eight knowledge areas are the ones this topic owns, and they are the two the whole domain leans on:

Generic names, brand names, and classifications of medications

That is KA 1.1, and

Indications of medications

That is KA 1.6. Read together they are one sentence: for any drug the exam names, you should know what it is called, what family it belongs to, and what it is for. Nothing here is arithmetic. This is the recall layer the rest of Domain 1 — interactions, side effects, dosage forms — is built on, and it is where the questions are cheapest to earn: a brand is paired with a generic, or a suffix is paired with a class, and one of the four answers is right.

Two facts make it easier than it looks. First, the generic name is not arbitrary: it is built from stems that were chosen to signal the class, so -olol is a beta blocker and -sartan is an ARB, whether or not you have ever seen the drug before. Second, the class tells you the indication far more often than the reverse: once you know a drug is a proton pump inhibitor, "reduces stomach acid" is not a guess, it is a consequence. Learn the stem, and you have bought the class and the use with it.

What this topic does not do. It does not teach mechanisms one by one — that is drug interactions and side effects and dosage forms, doses and storage. Here a drug's mechanism appears only where the name encodes it. The job is recognition: brand ↔ generic ↔ class ↔ why it is prescribed.

A drug has three names, and the exam uses all three

Three consequences follow, and each one is a question form:

• A combination product has one brand and several generics. Vicodin is hydrocodone/acetaminophen; Lotrel is amlodipine/benazepril. The generic name lists the ingredients, the brand does not.
• The brand is a moment in time; the generic is forever. Prozac was the brand for fluoxetine; the brand mark expires, the USAN does not. A patient's "my little purple pill" is not a name you can fill — which is why the first thing a technician does is translate it to a generic.
• One class, many indications. A class is not a use: an NSAID treats a sprain, arthritis and a fever. Learn the class, then the uses it covers.

Brand or generic, the same drug. Therapeutic equivalence is a Domain 2 concept (approved substitution, the Orange Book's codes) — this topic only has to know that the two names point at one drug, and that in most cases the pharmacist may substitute an equivalent generic.

The stem: how a generic name tells you its class

Most new single-entity drugs are named to a stem (also called an affix or infix): a syllable the USAN Council reserves for a family, so the name itself announces the class. The council's stated aim is that "similar compounds maintain a common 'family' name that provides immediate recognition" — which is exactly the exam's game, and exactly what the PTCE rewards with a suffix question.

Read the table as a habit, not a list. -flozin and -gliptin sit one letter apart in the middle — both treat type 2 diabetes — and mixing them is a common name confusion at the counter, so the stem is a safety feature as much as a study aid. Where two stems sound alike, the class is what tells you which drug does which job. Two more name endings worth knowing: carvedilol ends in -dilol, not -olol — a vasodilating beta blocker whose own stem (-dilol) marks the vasodilation — and ondansetron ends in -setron, the stem for the 5-HT3 receptor antagonists.

A prefix can carry the class too. Cephalosporins open with cef- or ceph- (cefdinir, cephalexin), and their generation is not in the name — first to fifth is a fact you learn separately. Biologics end in -mab — monoclonal antibody, and that is all the stem says: the older antibody names carried a target block inside them, but the newer ones do not follow that scheme, so do not read a disease out of a -mab name (the stem list even notes that -mab is being replaced by -bart, -mig, -ment and -tug on newer antibodies). The small-molecule parallel is -tinib, a tyrosine-kinase inhibitor. Recognition level is enough here: you are not asked to decode every infix, only to see that the name is telling you something.

There is one more stem system worth knowing because the exam leans on it: insulins are named by their second word, and the word is the product, not the class. Insulin lispro, insulin aspart, insulin glargine, insulin degludec are all insulins; lispro and aspart are rapid-acting, glargine is long-acting, degludec is ultra-long-acting. The class is in the first word, the onset/peak/duration in the second — which is why the two are never interchangeable on a prescription.

Stems that lie: the false friends

A stem is a pattern, not a law, and the exam knows the exceptions. Five that show up in a real pharmacy and in real questions:

Two more worth a line each, because they trip up a careful reader:

• -floxacin vs -flozin. levofloxacin is an antibiotic (a fluoroquinolone); dapagliflozin is a diabetes drug (an SGLT2 inhibitor). The names look alike on a shelf label and do completely different jobs — one of the classic look-alike/sound-alike pairs in Domain 3.
• -vir is a family, not a mechanism. acyclovir (a nucleoside analog), oseltamivir (a neuraminidase inhibitor) and ritonavir (a protease inhibitor) share the stem and share nothing else. The stem list itself carries 23 -vir sub-stems, each with its own definition — so the exam can ask for the class of a -vir drug, and the stem alone will not give it to you.

Classes a stem does not settle — these you memorize

The stem system has holes, and some stems are shared with a family that is not yours. For these families the drug names are the content: the stem does not decide the class, so a stem question becomes a recognition question.

The rule to carry into the exam: when a name gives you a stem, use it — the class and the use follow. When it gives you none, the drug is a name to be recognized, and the question will hand you the class or the indication one way or the other.

One drug, several brands: the suffixes and why they cannot be swapped

A drug's brand family is where a technician gets hurt, because the suffix is the only difference between two products with different strengths, different release and different directions. Toprol XL and metoprolol tartrate are the same drug as two different salts and releases (succinate extended-release vs tartrate immediate-release); Klor-Con and K-Tab are the same potassium salt; Adderall and Adderall XR are dosed completely differently.

The rule the suffix teaches: the suffix is part of the order, not decoration. Two products with the same stem and different suffixes are not interchangeable without the prescriber — and a tablet marked ER, XL or SR is a "do not crush" candidate (the forms, the in-use rules and the ISMP do-not-crush list are taught in dosage forms, doses and storage).

What the class is for: indications by family

KA 1.6 is small but it is scored, and it works in one direction: the class carries the indication. The table below is the layer to learn. Every line names the Top-200 drugs you should be able to place — and where a family has no Top-200 member, the drug is marked "not in the Top-200" rather than dropped. The source for all of it is the Top-200 drug list.

Brand and generic, across the Top-200

This is the recognition deck the topic is really about: every drug on the exam's most-prescribed list, its leading US brand, and the class the two names point at. It is derived from the Top-200 drug list, which carries the label source for each line — so any row here can be traced back to an SPL and a CMS claim count, and the brand column is a teaching brand, not the only brand the drug has.

The same 200 rows, ranked by 2024 claim volume with each drug's class beside it, also stand on their own page — the Top 200 drugs list — which is where to send a reader who wants the list itself rather than the stems and the false friends below.

How the exam asks KA 1.1 and KA 1.6

Four item forms carry almost all of this topic. Knowing the form is most of the work:

The distractor patterns to expect. Three are common enough to name:

1. A neighbor in the same stem. -flozin against -gliptin, or cefdinir against cefepime — same family, wrong member for the stated use.
2. A sound-alike from a different family. nystatin offered as a statin, or levofloxacin offered where dapagliflozin was meant.
3. A brand and a generic that do not match. Zestril (lisinopril) paired with losartan — the question is testing whether you read the brand, not whether you know the class.

Five mistakes this topic punishes.

• Reading the suffix as the whole answer. Toprol XL is metoprolol succinate, not metoprolol tartrate: the same drug, but a different salt, a different release, and different directions.
• Treating a class as one drug. "A beta blocker" is five drugs in the Top-200; the question will name one of them, so learn two or three members per class.
• Assuming the brand is gone because the generic exists. A discontinued brand is still a name a patient uses; Lasix is furosemide whether or not that brand is still marketed.
• Mixing the two words of an insulin. Insulin lispro and insulin glargine are not interchangeable at any dose — the second word is the prescribing decision.
• Learning names without classes. A name you can spell but cannot classify answers half the question forms and none of the safety ones.

Two sentences to carry out of this topic. Every drug has a generic name, a brand or several, and a class — and the class is what the name is usually trying to tell you. And: the class is the shortest route to the indication, so learn classes first and drugs second.

Where to go next

• Next topic — drug interactions and side effects
• The exam itself — the passing score, how many questions, and what makes the PTCB exam hard.

This topic sits inside Domain 1 — Medications, 35% of the exam — the outline's own weight, and PTCB publishes no per-knowledge-area split.

PTCE® is a registered trademark of the Pharmacy Technician Certification Board (PTCB). Elk Ridge Academy is not affiliated with or endorsed by PTCB.